Ascendis Pharma A/S (NASDAQ:ASND) Given New $201.00 Price Target at Bank of America
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by Bank of America from $196.00 to $201.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. Several other analysts have also recently weighed in on the company. Morgan Stanley raised Ascendis […]
Ascendis Pharma A/S (NASDAQ:ASND – Free Report) had its price objective raised by Bank of America from $196.00 to $201.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. Several other analysts have also recently weighed in on the company. Morgan Stanley raised Ascendis […]
